Literature DB >> 16410812

Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines.

H Funatsu1, H Yamashita, T Mimura, H Noma, S Nakamura, S Hori.   

Abstract

AIM: To ascertain whether vitreous and plasma levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and fundus findings could predict the outcome of vitreous surgery in patients with proliferative diabetic retinopathy (PDR).
METHODS: Vitreous fluid samples were obtained during vitreoretinal surgery from 73 consecutive eyes with PDR. The levels of VEGF and IL-6 in vitreous fluid and plasma were determined by enzyme-linked immunosorbent assay. Patients were prospectively followed for 6 months and the postoperative outcome was analysed by logistic regression analysis.
RESULTS: No improvement and/or progression of PDR occurred in 23 (32%) of the 73 eyes (progression group). The vitreous levels of VEGF and IL-6 were significantly higher in eyes from the progression group than in eyes with regression of PDR (regression group) (P=0.0032 and 0.0088, respectively). Multivariate logistic regression analysis showed that higher vitreous levels of VEGF were associated with the progression of PDR after vitreous surgery (odds ratio 2.72, P=0.0003).
CONCLUSIONS: High vitreous levels of VEGF identified as a significant risk factor for the outcome of vitreous surgery in patients with PDR. A model was developed to predict the probability of PDR progression and measurement of the vitreous level of VEGF may be useful for predicting the outcome of surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410812     DOI: 10.1038/sj.eye.6702213

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

1.  Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy.

Authors:  Xinxiao Gao; Kai Ma; Ning Lu; Yongsheng Xu; Tingting Hong; Xiaoyan Peng
Journal:  Mol Vis       Date:  2015-06-12       Impact factor: 2.367

2.  Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy.

Authors:  Jiaxing Wang; Song Chen; Feng Jiang; Caiyun You; Chunjie Mao; Jinguo Yu; Jindong Han; Zhuhong Zhang; Hua Yan
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

3.  CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.

Authors:  Takao Hirano; Yuichi Toriyama; Yasuhiro Iesato; Akira Imai; Toshinori Murata
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

4.  Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy.

Authors:  Faruk Nisic; Nina Jovanovic; Milka Mavija; Emina Alimanovic-Halilovic; Aida Nisic; Orhan Lepara; Adem Cemerlic
Journal:  Arch Med Sci       Date:  2018-02-02       Impact factor: 3.318

5.  The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.

Authors:  Tingting Jiang; Junxiang Gu; Peijun Zhang; Wenwen Chen; Qing Chang
Journal:  BMC Ophthalmol       Date:  2020-02-03       Impact factor: 2.209

6.  Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients.

Authors:  Hiroshi Izuta; Yuichi Chikaraishi; Tetsuo Adachi; Masamitsu Shimazawa; Tetsuya Sugiyama; Tsunehiko Ikeda; Hideaki Hara
Journal:  Mol Vis       Date:  2009-12-10       Impact factor: 2.367

7.  The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology.

Authors:  Stepan Rusnak; Jindra Vrzalova; Marketa Sobotova; Lenka Hecova; Renata Ricarova; Ondrej Topolcan
Journal:  J Ophthalmol       Date:  2015-09-27       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.